VivoSeq
Other

Miscarriage

30

Pipeline Programs↗

7

Active Trials↗

17

Companies Involved↗

Miscarriage is an emerging landscape with 30 programs across 17 companies. The most active players are Ferring, Iovance Biotherapeutics, Inc., Sanofi. 14 therapies are approved with 8 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

53/100

Pipeline Velocity

0/100

Mech. Concentration

15/100

Completion Rate

89/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Ferring logo

Ferring

1 program

Phase 2I

Iovance Biotherapeutics, Inc.

1 program

Phase 2Sanofi logo

Sanofi

2 programs

Phase 3Novo Nordisk logo

Novo Nordisk

1 program

Phase 3S

Solvay Pharmaceuticals

1 program

Phase 3D

Danco

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

52

clinical trials

Completed25 · 48%
Unknown status17 · 33%
Recruiting5 · 10%
Withdrawn2 · 4%
Active, not recruiting1 · 2%
Not yet recruiting1 · 2%
Other1 · 2%

Clinical Trials

Trial Activity

52 trials

Prednisolone Administration in Patients With Unexplained REcurrent MIscarriages
Recruiting·LLeiden University Medical Center·Phase 4·NCT05725512·490 enrolled
Determinants of Repeated Spontaneous Miscarriages and Unexplained Fetal Deaths
Recruiting·UUniversity Hospital, Brest·N/A·NCT04207814·200 enrolled
Use of Aromatase Inhibitor Before Misoprostol in Medical Termination of Miscarriage
Recruiting·—·N/A·NCT07109947·70 enrolled
Letrozole Plus Misoprostol Versus Misoprostol Alone for Treating Women With Missed Miscarriage
Recruiting·NNishtar Medical University·Phase 4·NCT07160855·92 enrolled
Hysteroscopy Versus Endouterine Aspiration in the Management of Trophoblastic Retention: A Prospective Randomized Multicenter Study
Recruiting·UUniversity Hospital, Montpellier·Preclinical·NCT05789940·220 enrolled
Miscarriage Preventing Herbal Medicines and the Risk of Birth Defects: a Population-based Cohort Study
Active, not recruiting·WWest China Hospital·N/A·NCT06048276·200,000 enrolled
Letrozole Versus Mifepristone and Misoprostol in Silent Miscarriage
Not yet recruiting·TThe University of Hong Kong·N/A·NCT06733727·884 enrolled
The HYsteroscopic Miscarriage MaNagement Trial: A Pilot RCT Investigating a Novel Management Pathway for RPOC
Completed·BBirmingham Women's and Children's NHS Foundation Trust·N/A·NCT04751500·149 enrolled
Misoprostol 400 µg Versus 200 µg for Cervical Ripening in 1st Trimester Miscarriage
Completed·HHospital de Clinicas de Porto Alegre·Phase 4·NCT02957305·211 enrolled
Estradiol Pretreatment With Misoprostol in Second Trimester Miscarriage
Completed·—·Phase 2/3·NCT03479879·200 enrolled
Trial of the Efficacy of Intravenous Immunoglobulin for Treating Women With Unexplained Secondary Recurrent Miscarriage
Completed·—·Phase 3·NCT00722475·82 enrolled
Evening Primrose Oil to Misoprostol During Induction of Second-trimester Missed Miscarriage
Completed·—·Phase 4·NCT03584698·144 enrolled
Pr-conceptional Progesterone for Unexplained Recurrent Miscarriage
Completed·WWoman's Health University Hospital, Egypt·Phase 4·NCT01670929·700 enrolled
Intralipid for Recurrent Miscarriage
Completed·WWoman's Health University Hospital, Egypt·Phase 4·NCT01788540·300 enrolled
Mifepristone and Misoprostol Versus Misoprostol Alone in the Medical Management of Missed Miscarriage
Completed·UUniversity of Birmingham·Phase 3·NCT03065660·711 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)